Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Shanghai Henlius Biotech, Inc. has signed a collaboration and license agreement with Palleon Pharmaceuticals to jointly develop and commercialize the drug E-602 and a combination therapy for human diseases globally, excluding China and its territories. The agreement includes milestone payments and royalties, with Shanghai Henlius granted the right of first negotiation for licenses in the Rest-of-Asia markets. This strategic partnership aims to enhance the companies’ market presence and drive growth in the biopharmaceutical sector.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.